Laurus Labs Limited

NSE LAURUSLABS.NS

Laurus Labs Limited Net Income Margin for the year ending March 31, 2024: 3.21%

Laurus Labs Limited Net Income Margin is 3.21% for the year ending March 31, 2024, a -75.46% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Laurus Labs Limited Net Income Margin for the year ending March 31, 2023 was 13.08%, a -22.73% change year over year.
Laurus Labs Limited Net Income Margin for the year ending March 31, 2022 was 16.93%, a -18.71% change year over year.
Laurus Labs Limited Net Income Margin for the year ending March 31, 2021 was 20.82%, a 125.04% change year over year.
Laurus Labs Limited Net Income Margin for the year ending March 31, 2020 was 9.25%, a 121.08% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NSE: LAURUSLABS.NS

Laurus Labs Limited

CEO	Dr. Satyanarayana Chava M.Sc., Ph.D.
IPO Date	Dec. 19, 2016
Location	India
Headquarters	Serene Chambers
Employees	6,007
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pet Food Plastics

Description

Laurus Labs Limited, together with its subsidiaries, engages in the development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C therapeutic areas. It also develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, PPIs, and central nervous system. In addition, the company provides contract development and manufacturing services for pharmaceutical companies; and manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. Further, it develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceutical field. The company was incorporated in 2005 and is based in Hyderabad, India.

Key trends

Past 5 years